untitled

® Advanced Technology
A fibrin sealant designed to stop severe bleeding. No need for pressure, staples or sutures.

Research Data Surgical Procedures

ClotFoam® is a second-generation fibrin sealant embedded in a highly adhesive scaffold; an advanced technology that bypasses fibrinogen cleavage, producing a strong fibrin polymer.

Indication
ClotFoam® is indicated for use in cases of severe hemorrhage in trauma, and in laparoscopy with potential applications in orthopedic surgery and interventional radiology.

Composition
It is a product in viscous liquid phase ready-to-use, composed of four parts containing the scaffold and fibrin components. When mixed through the applicator, the solutions form a foamy gel that anchors firmly to the bleeding site forming a stable clot.

Mode of Action
The foam technology allows non-invasive application and dissemination of the hemostatic agent in the peritoneal or other body cavities; adheres and compresses lacerated tissue to prevent flow of blood; and maintains the necessary components over the wound to produce a platelet plug, followed by a fibrin clot. Rapid formation of a strong hydrogel, effective cleavage, and instantaneous polymerization produce a firm clot.

Advantages
ClotFoam is a plasmin-depleted aprotinin-and-thrombin-free fibrin sealant presenting no risk of autoimmune reaction, and minimal risk of anaphylactic or systemic reaction to human blood products.

Unique characteristics

A non-compressible sealant technology: No need for sponges, patches, sutures or stitches.
ClotFoam can be used in cases of severe intracavitary hemorrhage, including liver trauma grade IV; laparascopic surgery; urinary, gynecological and brain surgical procedures.
Polymerizes almost instantly anchoring a strong clot over lacerated tissue.
Does not present thrombin to the immune system. It is plasmin depleted and does not require aprotinin.
It can be washed away after application, reducing inflammtory reaction to foreign body.

Developed with the support of the Defense Advanced Research Project Agency (DARPA), The National Heart, Blood, and Lung Institute (NHLBI) of the National Institutes of Health (NIH); The US Army Medical Research and Materiel Command (USAMRMC); the Maryland Technology Development Corporation (TEDCO ), and the University of Maryland.

® Advanced Technology	A fibrin sealant designed to stop severe bleeding. No need for pressure, staples or sutures.
	Research Data Surgical Procedures
	ClotFoam® is a second-generation fibrin sealant embedded in a highly adhesive scaffold; an advanced technology that bypasses fibrinogen cleavage, producing a strong fibrin polymer.
*Indication*	ClotFoam® is indicated for use in cases of severe hemorrhage in trauma, and in laparoscopy with potential applications in orthopedic surgery and interventional radiology.
*Composition*	It is a product in viscous liquid phase ready-to-use, composed of four parts containing the scaffold and fibrin components. When mixed through the applicator, the solutions form a foamy gel that anchors firmly to the bleeding site forming a stable clot.
*Mode of Action*	The foam technology allows non-invasive application and dissemination of the hemostatic agent in the peritoneal or other body cavities; adheres and compresses lacerated tissue to prevent flow of blood; and maintains the necessary components over the wound to produce a platelet plug, followed by a fibrin clot. Rapid formation of a strong hydrogel, effective cleavage, and instantaneous polymerization produce a firm clot.
*Advantages*	ClotFoam is a plasmin-depleted aprotinin-and-thrombin-free fibrin sealant presenting no risk of autoimmune reaction, and minimal risk of anaphylactic or systemic reaction to human blood products.
*Unique characteristics*	A non-compressible sealant technology: No need for sponges, patches, sutures or stitches. ClotFoam can be used in cases of severe intracavitary hemorrhage, including liver trauma grade IV; laparascopic surgery; urinary, gynecological and brain surgical procedures. Polymerizes almost instantly anchoring a strong clot over lacerated tissue. Does not present thrombin to the immune system. It is plasmin depleted and does not require aprotinin. It can be washed away after application, reducing inflammtory reaction to foreign body.
Developed with the support of the Defense Advanced Research Project Agency (DARPA), The National Heart, Blood, and Lung Institute (NHLBI) of the National Institutes of Health (NIH); The US Army Medical Research and Materiel Command (USAMRMC); the Maryland Technology Development Corporation (TEDCO ), and the University of Maryland.